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Exposure to childhood maltreatment increases the risk of developing mental illness later in life. Child-
hood maltreatment and depression have both been associated with dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axisda key regulator of the body's stress response. Additionally, HPA axis dys-
regulation has been implicated in the etiology of a range of mental illnesses. A substantial body of work
has shown history of childhood maltreatment alters DNA methylation levels within key HPA axis genes.
We therefore investigated whether one of these key genes, FKBP5 mediates the relationship between
childhood maltreatment and depression, and assessed FKBP5 DNA methylation and gene expression
within 112 adults from the Detroit Neighborhood Health Study (DNHS). DNA methylationwas assessed in
4 regions, including the upstream promoter, downstream promoter, and two glucocorticoid response
elements (GREs) via pyrosequencing using whole blood derived DNA; Taqman assays measured relative
RNA expression from leukocytes. Mediation analyses were conducted using sequential linear regression.
Childhood maltreatment was significantly associated with depression symptom severity (FDR < 0.006),
but was not a significant predictor of DNA methylation in any of the four loci examined. FKBP5 showed
elevated expression levels in participants with vs. without a history of depression (p < 0.001); no sig-
nificant difference in gene expression levels was observed in relation to childhood maltreatment
(p > 0.05). Our results suggest DNA methylation does not mediate the childhood maltreatment-
depression association in the DNHS.1. Introduction
Adverse early life experiences, such as childhood maltreatment
(CM), increase susceptibility for developing depression (Hussey
et al., 2006; Nanni et al., 2012; Nelson et al., 2017), post-
traumatic stress disorder (PTSD) (Stein et al., 1996), bipolar, Carl R. Woese Institute for
mpaign, 603 E. Daniel St, 527disorder (Afifi et al., 2008), and other mental health disorders
(MacMillan et al., 2001; Martin-Blanco et al., 2014; McGowan et al.,
2009) in adulthood. In addition, exposure to CM has been shown to
dysregulate the hypothalamic-pituitary-adrenal (HPA) axis, a
master regulator of the body's stress response (reviewed in (Van
Voorhees and Scarpa, 2004)). Substantial work has demonstrated
that dysregulation of the HPA axis increases the likelihood of
developing mood and anxiety disorders (Appel et al., 2011;
Ceulemans et al., 2011; Espejo et al., 2007; Guerry and Hastings,
2011; Nemeroff, 2004). Moreover, it has been well-documented
that exposures during early life, including CM, impact DNA
methylation (5mC) levels within genes of the HPA axis (Martin-
Blanco et al., 2014; McGowan et al., 2009; Romens et al., 2015; van
der Knaap et al., 2014) making the HPA axis a logical starting point
for studies examining the epigenetic impact of CM.
FK506 Binding Protein 5 (FKBP5) is a gene whose product is
involved in HPA axis function by negatively regulating the stress
response. The HPA axis is activated by stress and is regulated by two
levels of negative feedback: long range and ultra-short intracellular
feedback loops. Long range feedback occurs when high levels of
cortisol in the blood stream are detected by the hypothalamus,
resulting in decreased excretion of corticotropin releasing hormone
(CRH) and subsequent tamping down of the stress response
(Binder, 2009; Binder et al., 2008; Davies et al., 2002; Yang et al.,
2012). Ultra-short feedback occurs at the cellular level and in-
volves FKBP5, which acts as a negative regulator of the glucocor-
ticoid receptor (GR) (Appel et al., 2011; Binder, 2009; Binder et al.,
2008; Yang et al., 2012). The presence of FKBP5, when bound to a
multi-protein chaperone complex in the cytoplasm, lowers the
binding affinity between cortisol and the GR (Binder, 2009). When
cortisol is able to successfully bind to the GR, the GR-cortisol
complex translocates into the nucleus, where it binds to glucocor-
ticoid response elements (GREs) (Binder et al., 2008; Yang et al.,
2012) and acts as a transcription factor to upregulate FKBP5 tran-
scription. Increased expression of FKBP5 reduces GR sensitivity,
leading to more unbound cortisol in the cytoplasm and in the
blood, thereby activating the long feedback loop (Binder, 2009).
Despite FKBP5's prominent role in the regulation of the stress
response, relatively few studies have examined the relationship
between CM and FKBP5 5mC in humans. Klengel et al. (2013).
examined FKBP5 5mC in participants with a history of childhood
trauma compared to a control group. They reported significantly
decreased 5 mC at several glucocorticoid response elements (GREs)
and a significant interaction between childhood trauma exposure
and genetic variation at rs1360780 to predict 5 mC at intron 7
(Klengel et al., 2013). A second study, by Tyrka et al. examined the
association of CM and FKBP5 5 mC at intron 7 in a cohort of pre-
school aged children, and found significantly decreased FKBP5
5mC of two CpG sites within intron 7 and found no significant
interaction between SNP rs1360780 and lifetime contextual stress
on FKBP5 5mC of intron 7 (Tyrka et al., 2015). A third study in
children, by Weder et al. employed a genome-wide approach using
Illumina's 450K Bead Chip to examine 5mC and more broadly the
relationship between CM and depression (Weder et al., 2014). They
reported significant differences among CM cases compared to
controls at several CpG sites within FKBP5. However, due to the
incomplete coverage of the FKBP5 region by the 450K array, the
region examined in the two earlier studies was not assessed.
Two additional groups have examined FKBP5 5mC in relation to
other stressful life events. H€onhe et al. examined the impact of
psychosocial stress on FKBP5 5mC and gene expression (GE) within
the context of major depression history and FKBP5 genotype. They
found a significant interaction of SNP genotype at rs1360780 and
depression status on FKBP5 5mC of intron 7, however this finding
did not survive multiple test corrections (Hohne et al., 2015). Lastly,
Non et al. found the length of time in institutionalized care was
significantly negatively correlated with FKBP5 intron 7 CpG site 1
5mC after correcting for multiple hypothesis testing (Non et al.,
2016).
These studies reported significantly different FKBP5 5mC asso-
ciated with either exposure to CM or major depression, however
none of them directly examined the relationship among CM, 5mC,
and depressiondyet, given the demonstrated relationship between
CM and 5mC, as well as differential 5mC in relation to depression in
FKBP5 (Hohne et al., 2015) and other HPA axis genes (Na et al., 2014;
Nantharat et al., 2015; Tyrka et al., 2012), a plausible relation exists
among these factors. To address this possibility, we examinedwhether FKBP5 5mC mediates the relationship between CM and
depression, and if the altered 5mC subsequently influences GE
levels of FKBP5. Our primary analyses focused on the introns
implicated in previous work as being influenced by CM (Klengel
et al., 2013; Tyrka et al., 2015), while the FKBP5 promoter region
analyses reflect a smaller exploratory dataset that tested more ca-
nonical influences of 5mC on GE.
2. Methods
2.1. Participant selection
The Detroit Neighborhood Health Study (DNHS) was approved
by the institutional review board at the University of Michigan and
the University of North Carolina at Chapel Hill. Participants were
selected from the DNHS, a longitudinal, population-based repre-
sentative sample of adult residents from Detroit, MI (Goldmann
et al., 2011; Uddin et al., 2010). All participants provided
informed consent prior to participation. Selection for inclusion in
this study was based on the availability of whole-blood derived
DNA, leukocyte-derived RNA, and complete survey data regarding
CM and depression histories. The full sample (N ¼ 112) was tested
for intron 2 and intron 7, and a subset of participants (N ¼ 72) was
selected for the promoter region assays.
2.2. Childhood maltreatment
CM history was collected via structured telephone interviews
assessing the severity, duration, and frequency of each event type.
Assessment of CM was based on an adaptation of the Conflict
Tactics Scale (CTS) (Straus, 1979) and the Childhood Trauma
Questionnaire (CTQ) (Bernstein et al., 1997), as previously described
(Keyes et al., 2012; Uddin et al., 2013). CTS items assessed physical
and emotional abuse before age 11, with responses rated on a 5-
point scale. CTQ assessed physical and sexual abuse before age 18,
rating responses on a 3-point scale. In this study, a binary variable
of CM exposure was used, such that CM exposure (N ¼ 56) was
defined as any individual belonging to the upper quartile for CM
score within the full wave 2 DNHS survey sample (N ¼ 1588).
Participants without exposure to CM (N ¼ 56) belonged to the
bottom quartile of CM score within the full wave 2 DNHS survey
sample.
2.3. Depression measure
Depression symptom severity (depSS) scores were based on
participant responses from the Patient Health Questionnaire (PHQ-
9) (Kroenke et al., 2001), rated on a 4-point scale for each of the 9
questions with each question ranging from 0 (not at all) to 3 (nearly
every day); and total depression severity scores ranging from 0 to
27 as described in (Uddin et al., 2013). Lifetime major depressive
disorder (MDD) was assessed at each wave of the DNHS using the
PHQ-9, with additional questions to assess the timing and duration
of symptoms, consistent with DSM-IV criteria (American
Psychiatric, 1994) and previously validated (Uddin et al., 2011).
Participant depression information was taken from the same wave
as the participants’ biospecimens tested in the experiments
described below. In this study, the continuous measure of depSS
was used in the regression models. Within the GE analyses MDD
was defined as history of lifetime MDD.
2.4. Antidepressant medication
Participant medication information was obtained during the in-
home visit at the time of biologic sample collection and has been
described previously (Bustamante et al., 2016) and is included in
the regressions as a covariate.
2.5. Genotype
Participant genotype of FKBP5 SNP rs1360780was imputed from
data collected by the Illumina HumanOmniExpress BeadChip.
PLINK (Purcell et al., 2007) was used to impute the genotype of
rs1360780 for the DNHS participants. A subset of the study par-
ticipants (N ¼ 100) had available genotype information.
2.6. Sample preparation
2.6.1. DNA and RNA collection
Whole blood was collected via venipuncture from study par-
ticipants during scheduled in-home visits by a phlebotomist. DNA
was isolated from whole blood and concentration was verified via
Nanodrop 1000 (Thermofisher Scientific, Waltham, MA) as previ-
ously described (Bustamante et al., 2016). RNA was isolated from
leukocytes and subjected to the following criteria to ensure high
quality RNA was obtained, including a RNA integrity number (RIN)
5, 28s/18s  1.0, and 260/280  1.7 (Fleige and Pfaffl, 2006; Fleige
et al., 2006). RNA sample RIN values and 28s/18s ratios were
calculated using the 2100 Bioanalyzer (Agilent, Wilmington, DE) to
determine RNA quality.
2.6.2. Peripheral blood mononuclear cell counts
At the time of blood draw, two FICOLL gradient containing 8 ml
BD Vacutainers CPT™with sodium citrate (Franklin Lakes, NJ) were
used for the collection of peripheral blood mononuclear cell
(PBMC) samples and processed as previously described
(Bustamante et al., 2016).
2.6.3. Bisulfite conversion
Using Qiagen's Epitect Bisulfite Kit, 750 ng of participant DNA
was bisulfite converted following the manufacturer's recom-
mended protocol. Negative controls containing RNAse/DNAse free
water in place of DNAwere includedwith each bisulfite conversion.
High and low methylation control DNA purchased from Zymo
Research (Irvine, CA) was bisulfite converted along with the
participant samples in order to assess assay performance.
2.7. PCR amplification & pyrosequencing
5mC upstream of the transcription start site (TSS)
(CHR6:35,656,797e35,656,920), downstream of the TSS
(CHR6:35,655,829e35,655,843), and introns 2 (CHR6:35,558,310
e35,558,785) and 7 (CHR6:35,607,754e35,608,049) of FKBP5 were
assessed via pyrosequencing. These regions were targeted in part
based on: (i) previous work within FKBP5 (intron 2 and 7 (Klengel
et al., 2013):), and (ii) previous work demonstrating an association
between early life adversity and 5mC in promoter regions of related
HPA axis genes (i.e. NR3C1 (Oberlander et al., 2008; Tyrka et al.,
2012)). All assay files were designed and created using the Pyro-
Mark Q24 Assay Design Software 2.0 (Qiagen). 5mC of FKBP5's
Intron 2 and 7, which encompass GREs, has been previously
investigated by (Klengel et al., 2013; Tyrka et al., 2015; Yehuda et al.,
2015a) (Fig. 1). PCR and pyrosequencing primers for Intron 2 and 7
have been previously described in (Klengel et al., 2013). Due to the
read length of the assay associated with the intron 7 primers
developed by Klengel et al. intron 7 CpG 3methylation datawas not
reliably obtained; therefore, a new sequencing primer for Intron 7
CpG 3 was designed and used with the amplicon amplified by the
PCR primers as described by (Klengel et al., 2013). The two intron 2
CpG sites are both located near a consensus GRE sequence, ~552bpaway. Within intron 7 CpG sites 1 and 3 surround the consensus
GRE sequence: CpG 1 is 15bp away from the closest GRE consensus
sequence, and CpG 3 is 47bp away from the same GRE consensus
sequence; in contrast, CpG 2 is located within the consensus GRE
sequence. Within the promoter region, two separate loci were
examined. The first was a ready-made Qiagen assay targeting 3 CpG
sites within intron 1 and overlapped a CpG island TSS, denoted as
downstream promoter (Fig. 1). The second was newly developed
using the PyroMark Q24 Assay Design Software 2.0 (Qiagen). The
newly developed primer set encompassed 11 CpG sites within
several transcription factor binding sites (TFBS) including EGR-1,
and overlapped a CpG island upstream of the TSS, denoted as up-
stream promoter (Fig. 1).
All PCR and sequencing primers were validated according to the
recommendations in the PyroMark manual to ensure high quality
primers were used. Additionally, each primer set was tested using
commercially available Human high and low methylation control
DNA (Zymo Research) that was bisulfite converted on site. For each
locus examined, the high methylation control DNA averages and
ranges were: 91.1% for the upstream promoter with methylation
ranging from 74% to 100%; 96.7% for the downstream promoter
ranging from 92% to 100%; 76.1% for intron 2, ranging from 67% to
85%; and 96.4% for intron 7 ranging from 93% to 100%. The low
methylation control DNA averages and ranges were: 8% for the
upstream promoter, with methylation ranging from 2% to 32%; 6.6%
for the downstream promoter ranging from 5% to 8%; 27.9% for
intron 2, ranging from 27% to 30% intron 2; and 60.6% for intron 7
ranging from 54% to 68%. Bisulfite converted participant DNA was
amplified using Qiagen's PyroMark PCR kit for all four loci of FKBP5
examined in this study. PCRs were run in duplicate and contained
20 ng of bisulfite converted participant DNA as starting template.
No template controls were run in duplicate and were included with
each set of PCRs as a negative control as they did not contain any
DNA. Qiagen's PyroMark Q24 Pyrosequencer was used to detect
5mC levels followingmanufacturer's protocols and default settings.
Upstream Promoter Assays:
Upstream Promoter Primerset_1
Forward PCR primer (biotinylated): 50-AGGGTT-
TAGGGGTTGTTAGT-30
Reverse PCR primer: 50-TCCACCATCCCTTCTCTATAAC-30
Sequencing primer: 50-ATAATAAAAACCAAACCTCATTTAC-
30
Annealing temperature: 58 C
Targets 9 CpG sites
Upstream Promoter Primerset_2
Forward PCR primer: 50-AGGGTTTAGGGGTTGTTAGT-30
Reverse PCR primer (biotinylated): 50-TTTCCAC-
CATCCCTTCTCTATAAC-30
Sequencing primer: 50-GTTTATGTAAATGAGGT-30
Annealing temperature: 58 C
Targets 2 CpG sites
Downstream Promoter Assay:
Assay Name: Hs_FKBP5_01_PM PyroMark CpG assay
Qiagen Catalogue Number: PM00120946
Sequencing primer: 50- CGTTCAGCCGCTTCGG -30
Annealing temperature: 56 C
Targets 3 CpG sites
Intron 7 Assay:
FKBP5 Intron 7 CpG 3 sequencing primer: 50- AAGTTG-
TATTTTATTTTTTTAAGGA -30
Annealing temperature: 57 C
Targets 1 CpG site
Fig. 1. Schematic showing the four regions examined within the study indicated by shading upstream promoter (CHR6:35,656,797e35,656,920), downstream promoter
(CHR6:35,655,829e35,655,843), and introns 2 (CHR6:35,558,310e35,558,785) and 7 (CHR6:35,607,754e35,608,049). All coordinates provided are from the UCSC Genome Browser
Build 2009/hg19. The CpG sites examined within this study are indicated in uppercase, bold font, and green text. Lower case letters indicate intronic regions. Region of transcription
factor binding is indicated by underlined sequence. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Schematic showing the mediation framework for our analysis. Letters indicate
the order in which the regression models were tested. Note analysis “d” was only
tested for Intron 7.2.8. Reverse transcription & real-time PCR
FKBP5 mRNA expression levels were assessed in participants
with available total RNA (N ¼ 71). Total RNA was reverse tran-
scribed into cDNA following the manufacturer's protocol using the
High Capacity Reverse Transcription Kit purchased from Applied
BioSystems (Foster City, CA). Ready-made Taqman GE assays
(Applied Biosystems) were used to measure relative transcript
levels of the target gene FKBP5 (Hs015610061_m1) and the control
gene TATA Binding Protein, TBP (Hs00427621_m1) run in separate
wells. Reactions were performed in triplicate for each participant.
Each reactionwas 20 ml and contained 10 ng of participant cDNA for
both the test and control genes. Reactions were run on the HT7500
Fast Real-Time PCR machine (Applied BioSystems, Foster City, CA)
following the manufacturer's recommended protocol.
2.9. Pyrosequencing data analysis
5mC levels were averaged across CpG sites within each of the
four tested loci (upstream promoter, downstream promoter, intron
2, and intron 7). This step was performed based on the assumption
that CpG sites within a functional region, such as the promoter
region, a TFBS, or a GRE are correlated, based on previous empiricalevidence (Jones, 2012). Additionally, the composition of CpG sites
within intron 2 and 7 that were averaged correspond to the CpGs
included in the bins as reported by (Klengel et al., 2013). The dis-
tribution of averaged 5mC data obtained for each region was
evaluated using boxplots, histograms, and tested for normality
using the Shapiro-Wilk test of normality in IBM SPSS Statistics for
Windows, version 23.0 (IBM Corp., Armonk, NY).
2.9.1. Demographic statistics
Independent samples t-tests were used to test for bivariate as-
sociations between CM exposure and demographic covariates, as
well as depression and demographic covariates. Chi-square tests
were used to test for associations between CM exposure and the
demographic variables of sex, race, and genotype. Similarly, Chi-
square tests were used to test for the association between
depression history and sex, race, and genotype. All statistical tests
were two-tailed and results were considered significant when
p < 0.05. Tests were conducted using SPSS version 23.0.
2.9.2. Mediation analyses
5mC, CM, and depSS information for each participant was used
to carry outmediation analyses using linear regressions (Fig. 2). The
analysis was performed using SPSS version 23.0, following criteria
outlined in (Baron and Kenny, 1986). Specifically, we assessed
whether: (a) CM is associated with depSS after controlling for
confounders (i.e. age, sex, race, PBMC count, and antidepressant
medication use); (b) CM is associated with FKBP5 5mC levels, after
controlling for confounders; (c) if FKBP5 5mC is a predictor of
depSS, after controlling for confounders; and lastly, if a, b and c
were significant, we tested (a’), i.e. if the effect of CM on depSS at
FKBP5 regions is attenuated after controlling for 5 mC at those
regions, as well as other confounders. All regression models
included age, sex, self-reported race, PBMC count, and antide-
pressant medication information as covariates. A secondary anal-
ysis tested the potential interaction between CM and FKBP5 SNP
rs1360780 within intron 7, as previously reported in (Klengel et al.,
2013; Tyrka et al., 2015), in a subset of individuals with available
genotype data (n ¼ 100). For the model testing for an interaction,
the main effect model was run first, followed by the interaction
model. To address the concern of multiple hypothesis testing and
potential Type I errors, the false discovery rate (FDR) was calculated
as outlined in (Benjamini et al., 2001) such that results were
accepted as significant when FDR  0.006. Adjusted p-values are
indicated by “FDR” and unadjusted p-values are indicated by “p”.
2.9.3. Gene expression
Cycle threshold (CT) values for each sample were averaged
across replicates to obtain a mean CT value for each participant
used in our analysis. All data was examined for outliers, and any
replicates with a standard deviation greater than 0.25 were
removed (n ¼ 5), and the mean CT was re-calculated from the
remaining data points (Biosystems, 2016). GE data were analyzed
using the comparative CT method (Schmittgen and Livak, 2008),
normalizing FKBP5 GE against the control gene TBP. Normalized
data were analyzed using the student's t-test to compare expres-
sion levels according to exposure to CM and depression history. In
this secondary analysis, results were accepted as significant if
p < 0.05.
2.9.4. Correlation analysis
Pearson correlations were used to further explore the potential
relationship between FKBP5 GE and 5 mC at each of the four re-
gions examined individually. Correlations were considered signif-
icant when p < 0.05. Tests were conducted using SPSS version 23.0.
3. Results
General descriptive statistics of the study sample are included in
Table 1. Examination of the 5mC data revealed no extreme outliers.
Participants with exposure to CM were not significantly different
from those without CM exposure in terms of age, sex, self-reported
race, genotype (rs1360780), PBMC count, or percent methylation
(Table 1). There was a significant difference in CM score and depSS
for participants with a history of CM exposure compared to those
without such exposure (Table 1). Similarly, those with a history of
depression had significantly different CM score and depSS
compared to those with no reported history of depression (Table 1).
A subset of the study participants (N ¼ 100) had available genotype
information; of these, 16 participants were homozygous for the T
risk allele (i.e. TT), 41 participants were heterozygous CT, and 43
were homozygous CC. Participant genotypes were in Hardy-
Weinberg equilibrium (p ¼ 0.248). For SNP rs1360780, the major
allele is C and the minor allele is T. The minor allele frequency ac-
cording to the 1000 genomes project for rs1360780 is 0.3273
(Genomes Project et al., 2015), while in this dataset the imputed
minor allele frequency among participants is 0.365.
3.1. Mediation analysis
3.1.1. Upstream promoter
All analyses of the promoter regions, both upstream and
downstream, used the subsetted population of participants (N¼ 72,36 CM cases). In the upstream promoter analyses, we first tested
whether CM predicts depSS. CM was the sole significant predictor
of depSS in this model (b ¼ 4.78 SE 1.11 p < 0.001 FDR ¼ 0.005;
Table S1a). The next linear regression model tested the relationship
between CM and 5mC; neither our primary predictor (i.e. CM) nor
any of the covariates were significantly associated with 5mC within
this locus of the FKBP5 promoter region (Table S1b). The next
regression model tested whether 5mC predicted depSS; no signif-
icant predictors or covariates were identified in this model
(Table S1c). These results are summarized in Fig. 3A.
3.1.2. Downstream promoter
As with the upstream promoter region results, CM was the sole
significant predictor of depSS in this model CM (b ¼ 4.78 SE 1.11
p < 0.001 FDR ¼ 0.005; Table S2a). Similarly, there was no signifi-
cant relationship between CM or any of the covariates with 5mC;
and, no significant predictors were observed in the model exam-
ining whether 5mC predicted depSS (Tables S2bec). These results
are summarized in Fig. 3b.
3.1.3. Intron 2
All analyses of the intronic regions, both introns 2 and 7, drew
on the full sample population (N ¼ 112, 56 CM cases). In the first
model, CM (b ¼ 4.47 SE 1.44 p ¼ 0.002 FDR ¼ 0.006) significantly
predicted depSS (Table S3a). In the next models, CM was not a
significant predictor of FKBP5 Intron 2 5mC (Table S3b), nor did
FKBP5 intron 2 5mC predict depSS (Table S3c). These results are
summarized in Fig. 3C.
3.1.4. Intron 7
CM significantly predicted depSS (b ¼ 4.47 SE 1.44 p ¼ 0.002
FDR ¼ 0.006; Table S4a). Similar to intron 2, CM was not a signifi-
cant predictor of FKBP5 Intron 7 5mC (Table S4b). In the next
regression model, intron 7 5mC and other covariates did not
significantly predict depSS (Table S4c). Participant genotype was
available for a subset of participants (N ¼ 100, 50 CM cases); in-
clusion of participant genotype (rs1360780) as an interactor with
CM (as previously shown (Klengel et al., 2013)), did not alter the
reported non-significant findings (Fig. 3d; Supplementary Table 4).
3.2. Gene expression of peripheral leukocytes
FKBP5 GE was examined separately for CM and lifetime MDD to
discern the potential impact of each exposure. No significant
(p > 0.05) differences in relative GE levels were observed between
the CM exposed cases compared to the non-exposed controls.
However, when comparing MDD cases and controls, we observed a
significant increase in relative GE level among those with MDD vs.
controls (p < 0.001) (Fig. 4).
3.3. Correlation of gene expression and DNA methylation
The relationship between FKBP5GE and 5 mC at each of the four
regions was examined to further elucidate the relationship. No
significant (p > 0.05) correlation between FKBP5 GE and 5mC was
observed at any of the four loci examined: upstream promoter re-
gion r ¼ 0.036, p ¼ 0.812; downstream promoter region r ¼ 0.046,
p ¼ 0.759; intron 2 r ¼ 0.063, p ¼ 0.634; intron 7 r ¼ 0.091,
p ¼ 0.475.
4. Discussion
Previous studies have highlighted the importance of early life
environment in shaping mental health outcomes and have pro-
vided evidence that adverse early life experiences can impact 5mC
Table 1
Demographic, genetic, and survey data of the study participants. Values indicate the counts or mean ± standard deviation. Bold values indicate a significant (p < 0.05) dif-
ference between groups.
Measures Full Study Sample CM- CMþ p value*,
t-test or X2
MDD- MDDþ p value*,
t-test or X2
Total N ¼ 112
Age 50.74 ± 12.96 50.11 ± 13.14 50.14 ± 12.80 0.988 51.50 ± 13.32 47.65 ± 11.91 0.131
Sex X2 1 X2 0.257
Male 50 25 25 30 20
Female 62 31 31 42 20
Race X2 0.697 X2 0.971
European American 18 8 10 12 6
African American 86 43 43 55 31
Other 8 5 3 5 3
rs1360780 X2 0.782 X2 0.385
T Homozygous 16 9 7 12 4
CT Heterozygous 41 19 22 23 18
CC Homozygous 43 22 21 28 15
Depression Symptom Severity 8.28 ± 7.82 6.13 ± 7.31 10.47 ± 7.78 0.003 3.72 ± 4.98 16.38 ± 4.80 <0.001
PBMC count (million cells) 4.55 ± 1.49 4.50 ± 1.31 4.60 ± 1.68 0.719 4.46 ± 1.42 4.70 ± 1.61 0.432
CM Score 6.12 ± 5.43 1.57 ± 1.44 10.66 ± 3.93 <0.001 5.15 ± 4.79 7.85 ± 6.11 0.011
Percent DNA Methylation
Average Intron 2 76.40 ± 6.19 76.23 ± 5.94 76.61 ± 6.50 0.764 76.48 ± 6.95 76.30 ± 4.45 0.877
Average Intron 7 90.24 ± 3.02 89.98 ± 3.14 90.49 ± 2.92 0.397 90.01 ± 2.76 90.62 ± 3.42 0.326
N ¼ 72
Percent DNA Methylation
Average Upstream Promoter 4.64 ± 1.67 4.30 ± 1.45 4.75 ± 1.87 0.248
Average Downstream Promoter 2.80 ± 0.93 2.69 ± 0.91 2.90 ± 0.95 0.353
Depression Symptom Severity 3.72 ± 4.98 1.44 ± 2.2 6.06 ± 5.91 <0.001
CM Score 5.15 ± 4.79 0.75 ± 0.77 9.56 ± 2.48 <0.001
* Indicated p-values are derived from t-tests, unless denoted by X2, indicating it was derived by chi square test.
Fig. 3. Summary of the mediation analyses for each region of FKBP5 tested upstream promoter (a), downstream promoter (b), intron 2 (c), and Intron 7 (d). Significant results are
indicated by bold black text and denoted with both unadjusted p-values and FDR. Non-significant results are denoted by gray text and “N$S” for non-significant.levels within HPA axis genes. Motivated by this work, we sought to
test whether 5mC mediates the relationship between CM and
depSS in an adult population. We examined four loci within FKBP5
(upstream promoter, downstream promoter, intron 2, and intron
7); the latter two loci have previously shown CM-associated 5mC
differences. Our results suggest 5mC does not mediate the rela-
tionship between CM and depSS at any of the four FKBP5 lociexamined. However, and confirming a large body of previous
research in this area (Harkness and Monroe, 2002; Kessler et al.,
1997; MacMillan et al., 2001; Molnar et al., 2001; Wanklyn et al.,
2012), a significant effect of exposure to CM on depSS was
observed. These results highlight the complex relationship be-
tween CM and depression onset, suggesting multiple factors may
contribute to disease onset following exposure to CM.
Fig. 4. FKBP5 gene expression levels among individuals with (n ¼ 35) vs. without
(n ¼ 36) exposure to childhood maltreatment and participants with (n ¼ 25) vs.
without (n ¼ 46) lifetime major depressive disorder history. T-tests showed a signifi-
cant (p < 0.001) increase in gene expression levels among major depressive disorder
cases compared to controls. Error bars represent standard error and asterisk denotes
significant p < 0.05.Further examination of the individual regression analyses of the
larger mediation model revealed several surprising findings, the
first of which is that we did not detect a significant effect of CM on
FKBP5 5mC within intron 7 that has been reported in other studies
(Klengel et al., 2013; Tyrka et al., 2015). However, similar to our
findings for the promoter region, one previous study reported no
significant effect of CM on FKBP5 promoter region 5mC (Klengel
et al., 2013). The second surprising finding is that FKBP5 5 mC at
any of the 4 loci were not significant predictors of depSS. Several
studies have shown altered 5mC levels associated with depressive
mood (Kahl et al., 2016; Nantharat et al., 2015; Oberlander et al.,
2008; Tyrka et al., 2016). In addition, although the non-significant
interaction between CM and genotype (rs1360780) at intron 7 in
our data stands in contrast to previous work in adults (Klengel et al.,
2013), this finding is consistent with a study in children (Tyrka
et al., 2015). Further investigation is needed to elucidate the un-
derlying mechanism between CM and FKBP5 5mC.
As a secondary analysis, we examined the potential significant
functional effect of exposure to CM and lifetime MDD on FKBP5 GE
levels. No effect of CM exposure was observed on FKBP5 GE levels.
This finding is consistent with previous work that examined the
biological correlates of PTSD in a longitudinal military cohort on
FKBP5 GE and included CM as a covariate (van Zuiden et al., 2012).
Examination of FKBP5 GE levels in relation to lifetime MDD, how-
ever, revealed a significant increase in expression between those
with vs. without a history of the disorder. These findings are
consistent with previous studies examining rodent GE of Fkbp5 in
relation to chronic stress (Guidotti et al., 2013) or corticosterone
exposure (Lee et al., 2010). One human study that compared FKBP5
GE in pre- and post-antidepressant treatment in healthy controls
and depressed patients reported increased levels of FKBP5 GE at
baseline for the depressed patients compared to the healthy con-
trols (Cattaneo et al., 2013). Potential factors that may contribute to
the increase of FKBP5 GE associated with lifetime MDD include
cortisol, whichmay contribute to the observed association between
FKBP5 GE and MDD history. Cortisol is released into the blood-
stream from the adrenal glands when the HPA axis is activated
during stressful events, actual or perceived. Cortisol, when bound
to the GR increases transcription of FKBP5 via the ultra-short
intracellular feedback loop. High cortisol levels and aberrant HPA
axis regulation have been previously implicated in meta-analyses
and multiple studies (Belvederi Murri et al., 2014; Dienes et al.,2013; Stetler and Miller, 2011; Vreeburg et al., 2009), therefore, it
is plausible that our study participants with lifetime MDD have
altered cortisol sensitivity or HPA axis dysregulation, which con-
tributes to the association between FKBP5 GE and lifetime MDD.
Another potential mechanism contributing to this relationship is
non-coding RNAs, which can modulate GE (Kaikkonen et al., 2011;
Mattick and Makunin, 2006). Although our findings do not directly
assess these possibilities, our results do provide additional evi-
dence for the potential functional effect of depression on FKBP5 GE.
The potential functional effect of increased GE levels associated
with lifetime MDD may result in decreased sensitivity to cortisol,
possibly conferring higher GR resistance (Lopez-Duran et al., 2015;
Wei et al., 2015). In contrast, the non-significant effect of CM on
5 mC at any of the four loci suggests there is no apparent functional
effect of FKBP5 5 mC at these loci on FKBP5 GE levels, at least within
the DNHS study population, as evidenced by the correlation ana-
lyses. In the present study we report no significant association
between CM and 5mC in FKBP5, despite previous reports of an as-
sociation between these two factors.
One potential reason for our findings, which do not replicate
previous work, may pertain to the structure of our study. The popu-
lation used in this study is drawn from a community-based, popula-
tion-representative cohort, while the Klengel and Tyrka studies were
predominantly comprised of participants from lower socioeconomic
status. As such the level and types of trauma and/or contextual
stressors experienced by both cases and controls may differ from our
own population and impact results. Additionally, it is important to
note the average participant age within each study. Similar to our
study participants, the Klengel study is comprised of adults, whereas
the Tyrka study is comprised of pre-school aged children.Within this
study, the average age of DNHS participants was 50.74 years with
maltreatment assessed prior to the ages of 11 and 18, resulting in an
average of 32 years between exposure to CM and assessment of 5mC.
The Klengel study also used the CTQ to assess maltreatment prior to
the age of 18, however their populationwas on average younger than
ourDNHSparticipants, 41.46 years, resulting in anaverage of 22 years
between exposure to CM and assessment of 5mC. The Tyrka study, in
contrast, included pre-school aged children and relied on child wel-
fare records, rather than self-report, to assess CM. Given this infor-
mation, theKlengel study is themost comparable to the current study
in terms of CM assessment and age at 5mC assessment.
Another potential reason for non-replication may pertain to the
difference in the definition of what constituted CM. Selection of CM
cases within the Klengel study required histories of both sexual and
physical abuse, whereas within this study, selection was based off
of exposure levels defined by quartile, with no requirement
regarding the type or number of maltreatment types. The Klengel
study also reports a significant interaction of childhood trauma and
FKBP5 SNP in predicting lifetime PTSD status and modified PTS
symptom severity. Additionally, few studies have examined the
impact of PTSD on 5mC in FKBP5 (Yehuda et al., 2013) and other
HPA axis genes (Labonte et al., 2014; Yehuda et al., 2015b), therefore
it is possible that co-morbid lifetime or current PTSD may be
driving some of the reported significant findings in the earlier
work. As a result, careful interpretation and comparison is required
for our own findings as well as those reported by others.
There are study limitations that should be noted. First, the CM
variable used in our study is a retrospective self-reported measure
of abuses occurring before age 18. Early life experiences have been
shown to be long lasting, with effects detected into adulthood,
however self-reported measures may introduce recall bias. Previ-
ously, retrospective self-reports of CM from adults with docu-
mented cases were associated with underreporting of physical and
sexual abuse (Widom andMorris,1997;Widom and Shepard,1996).
Therefore, our measure of CM may well be an underestimate of
previous abuse. Second, the use of self-reported measures may
include heterogeneity and variability within the reported partici-
pant results for both measures of CM and depression, which may
contribute to our reported null findings. Despite this possibility, the
CM measure and a similar measure derived from the PHQ-9 for
MDD were adequate to detect significant associations in our own
previous work (Bustamante et al., 2016). Third, it is possible that our
study was underpowered to detect the associations being explored
within this work. Nevertheless, we do not believe this to be a likely
explanation: the sample size used in this study, N¼ 112, is between
the reported samples sizes for Klengel (N¼ 76) and Tyrka (N¼ 174)
which both reported significant findings for FKBP5. Moreover, a
post-hoc power calculation shows that the sample is adequately
powered (86.5%) to detect medium effects sizes as determined by
G*Power (Faul et al., 2009). Fourth, we were unable to control for
white blood cell subset within our study; however, we were able to
include PBMC counts in each regression model. Notably, there was
no significant difference in PBMC counts between participants with
vs. without exposure to CM or with vs. without a history of
depression. Lastly, we were unable to assess whether our findings
were associated with differences in participant cortisol level, as
cortisol was not collected within the parent study, the DNHS.
Recent work suggests there is a genotype-dependent cortisol
response to stress associated with FKBP5 SNP rs1360780
(Buchmann et al., 2014; Fujii et al., 2014; Hohne et al., 2015).
The DNHS is a non-clinical, community-based cohort of adults
Detroit, Michigan residents. As such, this study provides us the
opportunity to generalize our findings to the larger Detroit popu-
lation. Second, our study is unique because antidepressant medi-
cation use is a covariate in our analyses; inclusion of this variable
allows us to adjust for the potential effect of antidepressant
medication on 5mC levels as previously reported (Melas et al.,
2012; Perisic et al., 2010). Third, this study adds to the literature
by examining the relationship among CM, 5mC, depSS, and GE,
with additional analyses examining FKBP5 genotype and its po-
tential interaction with CM. Lastly, we measured 5mC and GE in a
subset of the same study participants, which allowed us to infer the
potential impact of altered 5mC downstream on FKBP5 GE.
In conclusion, we found that 5mC in multiple genomic regions
of FKBP5, a regulator of GR sensitivity, does not mediate the rela-
tionship between CM and depSS. We also found a significant in-
crease in FKBP5 GE levels associated with lifetime MDD.We did not
however, observe any significant difference in relative GE levels
related to exposure to CM. Taken together, these results suggest
other, additional factors beyond 5mC likely mediate the relation-
ship between CM and depression as detectable in blood. Future
studies would benefit from the examination of participant cortisol
levels to further assess the implications of altered FKBP5 GE within
individuals with a history of MDD. Additionally, examination of
5mC within other regulatory regions of FKBP5 is critical to further
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